Pomalidomide is used for treating multiple myeloma in patients who have already received other prior therapies. It was first introduced by Bristol Myers Squibb Co in its drug Pomalyst on Feb 8, 2013. 7 different companies have introduced drugs containing Pomalidomide.

Pomalidomide Patents

Given below is the list of patents protecting Pomalidomide, along with the drug name that holds that patent and the company name owning that drug.

Download patent list as spreadsheet

Get the complete list right in your inbox!

Drug Used in	Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Drug Owner
Pomalyst	US8828427 (Pediatric)	Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione	Dec 21, 2031	Bristol
Pomalyst	US8828427	Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione	Jun 21, 2031	Bristol
Pomalyst	US10555939 (Pediatric)	Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione	Nov 19, 2030	Bristol
Pomalyst	US9993467 (Pediatric)	Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione	Nov 19, 2030	Bristol
Pomalyst	US10555939	Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione	May 19, 2030	Bristol
Pomalyst	US9993467	Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione	May 19, 2030	Bristol
Pomalyst	US8198262 (Pediatric)	Methods for treating multiple myeloma using 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione	Dec 17, 2025	Bristol
Pomalyst	US8198262	Methods for treating multiple myeloma using 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione	Jun 17, 2025 (Expired)	Bristol
Pomalyst	US8673939 (Pediatric)	Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione	Nov 15, 2023 (Expired)	Bristol
Pomalyst	US8735428 (Pediatric)	Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione	Nov 15, 2023 (Expired)	Bristol
Pomalyst	US8673939	Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione	May 15, 2023 (Expired)	Bristol
Pomalyst	US8735428	Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione	May 15, 2023 (Expired)	Bristol
Pomalyst	US6315720	Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug	Oct 23, 2020 (Expired)	Bristol
Pomalyst	US6561977	Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated	Oct 23, 2020 (Expired)	Bristol
Pomalyst	US6755784	Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated	Oct 23, 2020 (Expired)	Bristol
Pomalyst	US8315886	Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated	Oct 23, 2020 (Expired)	Bristol
Pomalyst	US8626531	Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated	Oct 23, 2020 (Expired)	Bristol
Pomalyst	US6045501	Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug	Aug 28, 2018 (Expired)	Bristol
Pomalyst	US6561976	Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug	Aug 28, 2018 (Expired)	Bristol
Pomalyst	US6908432	Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug	Aug 28, 2018 (Expired)	Bristol
Pomalyst	US8204763	Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug	Aug 28, 2018 (Expired)	Bristol
Pomalyst	US8589188	Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug	Aug 28, 2018 (Expired)	Bristol
Pomalyst	US6316471	Isoindolines, method of use, and pharmaceutical compositions	Aug 10, 2016 (Expired)	Bristol
Pomalyst	US8158653	Pharmaceutical compositions of 1,3-dioxo-2-(2,6-dioxopiperidin-3-yl)-4-amino isoindoline	Aug 10, 2016 (Expired)	Bristol
Pomalyst	US5635517	Method of reducing TNFα levels with amino substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxo-and 1,3-dioxoisoindolines	Jul 24, 2016 (Expired)	Bristol
Pomalyst	US5653517	Process and system for determination of friction/slip characteristics of road vehicle tires	Jul 24, 2016 (Expired)	Bristol
Pomalyst	US6476052	Isoindolines, method of use, and pharmaceutical compositions	Jul 24, 2016 (Expired)	Bristol

Add above patents to watchlist

Pomalidomide's Family Patents

Full family tree

Pomalidomide Generic API Manufacturers

Several generic applications have been filed for Pomalidomide. The first generic version for Pomalidomide was by Breckenridge Pharmaceutical Inc and was approved on Oct 30, 2020. And the latest generic version is by Hetero Labs Ltd Unit V and was approved on Sep 26, 2024.

Given below is the list of companies who have filed for Pomalidomide generic, along with the locations of their manufacturing plants worldwide.